Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Wendtner

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Gene Therapy|July 1, 1997
Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell responseC M Wendtner, A Nolte, E Mangold, et al.
Deutsche Medizinische Wochenschrift (1946)|July 13, 2016
[Louse-borne-relapsing-fever in refugees from the Horn of Africa; a case series of 25 patients]M Seilmaier, W Guggemos, A Wieser, et al.
Human Gene Therapy|June 2, 1998
Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cellsG Maass, C Bogedain, U Scheer, et al.
Der Internist|January 15, 2003
[Chronic lymphatic leukemia. Current therapy concepts]M Hallek, M Bergmann, G Brittinger, et al.
Leukemia|July 24, 2009
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaA Osterborg, R Foà, R F Bezares, et al.
Leukemia|September 3, 2011
Action of novel CD37 antibodies on chronic lymphocytic leukemia cellsG Krause, M Patz, P Isaeva, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2009
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinibM Montemurro, P Schöffski, P Reichardt, et al.
Leukemia|April 9, 2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)C-M Wendtner, M Ritgen, C D Schweighofer, et al.
Leukemia|October 16, 2019
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemiaM Fürstenau, J Bahlo, A M Fink, et al.
Leukemia|May 3, 2016
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLLC Maurer, P Langerbeins, J Bahlo, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Gene Therapy|July 1, 1997
Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell responseC M Wendtner, A Nolte, E Mangold, et al.
Deutsche Medizinische Wochenschrift (1946)|July 13, 2016
[Louse-borne-relapsing-fever in refugees from the Horn of Africa; a case series of 25 patients]M Seilmaier, W Guggemos, A Wieser, et al.
Human Gene Therapy|June 2, 1998
Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cellsG Maass, C Bogedain, U Scheer, et al.
Der Internist|January 15, 2003
[Chronic lymphatic leukemia. Current therapy concepts]M Hallek, M Bergmann, G Brittinger, et al.
Leukemia|July 24, 2009
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaA Osterborg, R Foà, R F Bezares, et al.
Leukemia|September 3, 2011
Action of novel CD37 antibodies on chronic lymphocytic leukemia cellsG Krause, M Patz, P Isaeva, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2009
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinibM Montemurro, P Schöffski, P Reichardt, et al.
Leukemia|April 9, 2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)C-M Wendtner, M Ritgen, C D Schweighofer, et al.
Leukemia|October 16, 2019
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemiaM Fürstenau, J Bahlo, A M Fink, et al.
Leukemia|May 3, 2016
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLLC Maurer, P Langerbeins, J Bahlo, et al.
Pageof 8